Abstract The prenatal determination of the fetal Rh genotype could lead to a substantial reduction in the use of anti-D immunoglobulin and prevention of unnecessary exposure of pregnant women carrying RhD negative fetus. The aim of this study was fetal RHD genotyping through the analysis of cffDNA in plasma samples of RhD negative pregnant women by real-time PCR technique. In this experiment, 30 plasma samples were collected from RhD negative pregnant women. DNA were extracted and realtime PCR reactions were done by specific primers for RHD, SRY and beta-globin (GLO) genes. The Rh phenotypes of mothers and their babies were determined by agglutination method and specific anti-serums. From the 30 maternal plasma samples considered for SRY genotyping, 16 samples revealed the presence of the SRY gene. Regarding the fetal RHD genotyping, 26 samples were positive for RhD and 4 samples were negative. In all cases, the predicted RhD and SRY genotypes were in concordance with the serologically determined phenotypes. The sensitivity, specificity and precision of the fetal RHD and SRY genotyping test were calculated 100 % (p value \0.0005; K = 100 %). The present study confirms the precision of fetal RHD and SRY genotyping in maternal plasma by real-time PCR technique. This method helps RhD negative pregnant women about the appropriate use of anti-D immunoglobulin and also on the management and prevention of HDFN. However, superior and confirmatory studies are recommended before fetal RHD genotyping by real-time PCR is introduced as a non-invasive prenatal screening test.
Introduction
The Rh blood group is one of the most complex and polymorphic blood groups known in humans [1] . The homologous genes RHD and RHCE are encoding two distinct Rh proteins which are located on chromosome 1. These genes each have 10 exons and 9 introns and share 96.8 % homology at the nucleotide level [2] [3] [4] .
This system includes more than 50 antigens and it is the most clinically significant blood group after the ABO system. Besides its significant role in transfusion medicine, the Rh blood group system, specifically the D antigen, is closely related to the most severe form of hemolytic disease of the fetus and newborn (HDFN) [5] .
Approximately, 50 % of cases of maternal alloimmunization are originates from maternal anti-D (IgG) antibody that crossing the placenta and binding to RHD-positive fetal RBCs which leads to their destruction following by anemia and in some cases contributes to hydrops fetalis and intrauterine fetal death or neonatal death [5, 6] . Therefore, feto-maternal rhesus (Rh) incompatibility still represents the major cause of HDFN.
Since postnatal anti-D prophylaxis was introduced in the 1970s, the incidence of RhD immunization decreased from 14 % to approximately 0.8-1.5 % in RhD negative pregnant women. In many countries combined use of prenatal offered in the beginning of the third trimester of pregnancy and postnatal prophylaxis has resulted in further reduction in the immunization risk to roughly 0.2-0.4 % [7, 8] .
Rh immunoglobulin is derived from pooled human plasma, therefore, the risk of transmission of infectious agents may exist. Consequently, efforts should be made to avoid superfluous exposure in order to reduce the risk of infection [9] [10] [11] [12] .
In many countries, including Iran, it is common practice that all RhD negative pregnant women with RhD positive husband are offered antenatal anti-D immunoglobulin prophylaxis because RhD phenotype of the fetus is not specified until birth. It should be noted that a significant percentage of pregnant women carries RhD negative fetus and in other words they receive unnecessary immunoglobulin D [13] .
By determining the genotype of fetal RhD, anti-D immunoglobulin can be administered purposefully to RhD negative pregnant women who carries RhD positive fetus [14] [15] [16] [17] . Another advantage of genotyping fetal RhD is about women who immunized against the D antigen for various reasons and have anti-D in their serums. For these individuals, if it is determined that fetus has negative RhD, there is no risk of HDFN. Therefore, some invasive actions including amniocentesis, cordocentesis and preterm delivery could be prevented. Moreover, if positive fetal RhD is reported, essential measures will be taken into account in order to provide timely and appropriate medical care [1, 18] .
With the discovery of cell free fetal DNA (cffDNA) in the plasma of pregnant women by Denis Lo in 1997, the possibility of fetal RHD genotyping was achieved in a noninvasive method [19] . cffDNA enter the mother's bloodstream and its origins are often apoptotic macro vesicles which are separated from trophoblast cells of placenta [20] [21] [22] [23] . Notably, cffDNA is present in the maternal circulation in limited quantities. A very low cffDNA level is detectable from the seventh week of gestation and its value amplifies with increasing gestational age. Eventually, it is completely vanished from mother's blood stream within 1-2 days after delivery [24] [25] [26] .
Fetal RhD genotyping can be done with conventional PCR methods, however, real-time PCR technique has a greater accuracy, specificity and sensitivity in comparison [27, 28] .
The objective of the current study was to evaluate the concordance between fetal RhD genotyping by real-time PCR method on extracted cffDNA from maternal plasma and the newborn's RhD phenotype through serologic tests.
Materials and Methods

Sample Collection and Processing
After informed consent was obtained, venous blood samples were collected from 30 RhD negative pregnant women with RHD positive partner that attended the routine obstetric care at two maternity hospitals in Tehran. From each pregnant woman, 5 ml peripheral blood were collected into tubes containing K3-EDTA.The plasma was separated from whole blood by centrifugation at 3000g for 10 min within \2 h after collection. Collected plasma was re-centrifuged with the same speed and duration and the supernatant was stored in a new microtube at -80°C until required.
DNA Extraction/Purification
DNA was extracted from plasma using a QIAamp DNA Blood Mini Kit (Qiagen, Germany) according to the manufacturer's recommended protocol. Finally, the column-bound circulatory DNA was eluted with 50 ll buffer AE and stored at -20°C until further processing. Isolated DNA was quantified in NanoDrop Spectrophotometer (Wilmington, DE) by absorption at 260 and 280 nm.
Real Time PCR
All samples were evaluated for the fetal sex and RhD genotype by real-time PCR using specific primers synthesized by Eurofins Genomics (Germany) ( Table 1) . Primers were designed so that the PCR products length were \140 bp that is shorter than the mean size of cffDNA (145-201 bp).
To increase the specificity of the assay, three regions of the RHD gene (exons 5, 7 and 10) were investigated. To confirm the presence of DNA in the sample and presence of male fetal DNA, beta-globin (GLO) and SRY genes were included in our study respectively.
Real-time PCR reactions were performed in QIAGEN's real-time PCR cycler (Rotor-Gene Q) (QIAGEN, Germany) with SYBR Green PCR Master Mix (Amplicon, Denmark). Each amplification reaction was prepared in a final volume of 20 ll, containing 5 ll of purified plasma DNA, 10 ll of 2X SYBR Green Master Mix and 0.5 ll of each primer (10 lM).
The PCR conditions were programmed with an initial step of denaturation at 95°C for 5 min, followed by 50 cycles of 95°C for 15 s, 61°C for 30 s and 72°C for 30 s. Melting curve analysis verified the real-time PCR amplification and electrophoresis on 2 % agarose gel confirmed it as well.
In order to increase the sensitivity of the technique, the genotyping was performed in triplicate for all reactions. Each assay was included a negative control (female individual with ccddee phenotype), a positive control (male individual with ccDee phenotype) and a no-template control (NTC).
Amplification plots of each RHD exon, SRY and GLO genes for patient samples were analyzed and Cycle threshold (C t ) values lower than 42 were accepted as positive. RhD genotyping analysis was performed as follows: if at least 2 out of the 3 replicates of each exon were positive, we considered the fetus was carrying the paternal RHD gene. In cases where all replications were negative or inconsistency between replicates was observed for instance just one replication was positive, real-time PCR reaction was repeated in another triplicate run with new extracted samples. If all the reactions of RHD exons were negative, the fetus was considered RhD negative when the presence of genomic DNA was confirmed by GLO and SRY genes. A fetus was considered male if at least 2 out of 3 replications for SRY gene were positive.
If the difference between any C t value for RHD exons and GLO gene was \2, this could indicate that the mother has an unexpressed RHD gene and the test result is considered unreliable and further investigation should carried out using the maternal genomic DNA [14] . In cases that fetus is RhD positive, the calculated Ct for RHD gene is at least 4-6 values higher than the Ct for the control gene (GLO) [29] .
Confirmation of the Fetal D Status and Sex
Peripheral or umbilical cord blood samples were collected from neonates at birth and serologic tests were performed in order to determine the RhD phenotype. In addition, the neonate's sex was also obtained at birth.
Statistical Analysis
The results were analyzed by SPSS 22 software (SPSS Inc., Chicago, USA) using the Chi square of independence test and Cohen's Kappa which relate the concordance between obtained and expected results and p value \0.05 was considered statistically significant. Diagnostic measures were also used, such as sensitivity, specificity and precision/accuracy.
Results
The 30 RhD negative pregnant women included in the current study were in a gestational period between 8 and 36 weeks and were aged from 19 to 30 years (mean 25.4 ± 3.2). Of these, 6 cases (20 %) were assessed during the 1st trimester, 13 persons (43.33 %) were tested during the 2nd trimester and 11 individuals (36.67 %) were evaluated during the 3rd trimester of pregnancy (Table 2) .
Comparatively to the blood group typing, it was found that 25 (83.33 %) pregnant women had the ccddee phenotype, 3 (10 %) had the Ccddee phenotype and 2 (6.67 %) had the CCddee phenotype ( Table 2 ).
All women reported not having received blood transfusion in the last 3 months and never having done a transplant. Both of these could probably lead to alteration in the genotyping results because of the possibility of evaluating the donor's DNA instead.
Real-time PCR genotyping results were compared to the serological analysis of peripheral or umbilical cord bloods from neonates at birth. From the 30 children considered for Regarding the prenatal fetal RHD genotyping by realtime PCR, 26 (86.67 %) samples were positive for RhD and 4 (13.33 %) samples were negative. In all cases, the anticipated RHD genotypes were in concordance with the serologically determined phenotypes. Therefore, the sensitivity, specificity and precision of the fetal RHD genotyping test were calculated 100 % (p value \0.0005; K = 100 %).
From the 30 maternal plasma samples considered for SRY genotyping, 16 (53.33 %) revealed the presence of the SRY gene and 14 (46.67 %) were negative for this gene.
There was 100 % concordance between fetal sex genotyping by real-time PCR and newborn's sex. As a result, the sensitivity, specificity and precision were calculated 100 % for the SRY gene detection (p value \0.0005; K = 100 %). The GLO gene was detected in all samples.
Discussion
In the present study, evaluating fetal RhD genotype in 30 samples of DNA which were extracted from the plasma of RhD negative pregnant women revealed that 86.67 % of the samples was RhD positive and 13.33 % of them was RhD negative. These results were in complete concordance with the results of serology after birth and can be concluded that genotype identification of fetal RhD through detection of cffDNA by real-time PCR is a noninvasive and safe technique with high sensitivity and specificity.
There are many challenges in fetal RhD genotyping that they play important role to achieve accurate results in this filed. Since the Rh system is very complex, there are always the possibility of false positive and negative results which should be seriously considered.
Generally, determining the polymorphisms of a gene and their frequencies in a specific population is an important stage in fetal RHD genotyping and no related study has been done so far in Iran. Therefore, exon selection and primer design are imperative steps that help to determine the RHD genotype accurately which could be accomplished through the experiences of other researchers and validated articles about this issue [30] . For instance, other researchers suggested to assess at least two exons of RHD in order to avoid false negative results [31, 32] . A. Aykut et al. evaluated genotype of fetal RHD in 2013 by using the primers of exons 7 and 10 and their results were in accordance with the serological findings after birth [33] .
In the present study, exons 5, 7 and 10 were selected. The reason for using exon 10 with exon 5 and 7 is that exon 10 remains unchanged in most of variants of RHD hybrid genes; therefore, the possibility of a variant of RHD gene is suggested when the results of exon 5 and 7 are negative and exon 10 is positive in real-time PCR. Thus, false negative results in determining RHD genotype could be preventable with selecting precise exons [30] .
Due to the similarity of approximately 96 % between RHD and RHCE genes, primers should be selected in such a way that they are capable of distinguishing between these two genes well. In the current study, primers are selected according to the nucleotide sequence of these two genes and information in other literatures in order to avoid regions of cross homology and design specific primers for RHD gene that do not have the ability to replicate the RHCE gene [1, 34] .
Another concern in fetal RHD genotyping that should be deliberated is the concentration of cffDNA. One of the main reason of false negative results in determining the fetal RHD genotype is related to the very low concentration of cffDNA in mother's plasma. The amount of cffDNA in plasma escalates especially in the last 3 months of pregnancy with increasing the gestational age. Therefore, when the fetal RHD genotype were identified as negative in the early weeks of pregnancy, it may be owing to the low concentration of cffDNA and it should be repeated a few weeks later by resampling in order to confirm the obtained result [35, 36] .
Using especial gene as a control is necessary in order to confirm the presence of total DNA (fetal and maternal DNA) in mother's plasma. However, it should be noted that using these genes only indicate the presence of DNA in plasma and it cannot differentiate fetal DNA from maternal DNA. Beta-globin (GLO) gene was used in this study [37] .
In order to differentiate fetal DNA from maternal DNA and in other words confirm the presence of cffDNA in mother's plasma, we need a marker that is specifically for fetus and present in mother's plasma. One of the markers that is used in this field is SRY gene on chromosome Y. The presence of SRY gene in mother's plasma show the presence of male fetus in mother's uterus as well as confirm the presence of cffDNA in mother's plasma [1, 36] .
Wang et al. studied the genotype identification of fetal RHD with real-time PCR in 2009. Beta-globin and SRY genes were used as a control and presence of fetal DNA respectively in their study. 52.56 % of the samples indicated positive SRY that were consistent with the sexuality of infants after birth. In other words, they approved the presence of fetal DNA in 41 samples of 72 [37] . In the present study, detection of SRY gene was done by real-time PCR method, 53.33 % of the samples exposed the presence of the SRY gene and results were in complete agreement with the gender of infants after birth and approve the presence of fetal DNA.
However, when mother has female fetus with negative genotype of RHD, using SRY marker in order to approve the presence of cffDNA is not helpful [1] . RASSF1A (RAS association family 1 A) is a tumor suppressor gene which could be a useful marker in order to solve this problem and detect fetal DNA specifically. Promoter of this gene is hyper methylated in fetal DNA, conversely it is hypo methylated in maternal DNA; therefore it is a suitable marker in order to identify fetal DNA [38, 39] . Treatment of DNA with the methylation-sensitive restriction enzyme BstU1 results in digestion of an RASSF1A promoter sequences derived from maternal DNA, but not that from placental, and therefore fetal DNA. The undigested sequences could then be detected by real-time PCR in a multiplex with the test for RHD [31] .
It should be noted that the limitation of our study was the absence of an appropriate control gene (such as RASSF1A) in order to approve the presence of fetal DNA in situations that all real-time PCR results except betaglobin are negative. It is hoped that this issue will be addressed in future studies.
Conclusion
This study approve the accuracy of fetal RHD genotyping in mother's plasma without any false negative result. Genotype identification of fetal RHD gene can be useful and practical for various reasons in clinical and laboratory centers. Firstly, unnecessary injection of immunoglobulin D in pregnant women with RHD negative fetus which consist 13.33 % of the samples in our study can be prevented in the future. Secondly, invasive methods could be prevented in sensitized pregnant women with anti D who have RhD negative fetus. Thirdly, necessary and timely diagnostic actions could be taken among mothers with RhD positive fetus. Additionally, identifying the genotype of fetal RHD is helpful in some cases that the phenotype results of infant's RhD are reported false negative and timely injection of Rhogam prevent HDFN in subsequent pregnancies.
Conducting similar investigations with larger sample size could allow the implementation of this specific, sensitive and non-invasive prenatal diagnostic test in clinical laboratory routine in Iran. However, in order to assess the usefulness of this test it must be determined first that RHD and SRY genotyping in Iran is economically affordable or not.
